Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

Open Access 01-05-2016 | Research Article

Wnt5a and Ror2 expression associate with the disease progress of primary thyroid lymphoma

Authors: Lei Wang, Dong Yang, Ying-Hou Wang, Xi Li, Hong-Ming Gao, Jun-Yuan Lv, Lei Wang, Shi-Jie Xin

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Primary thyroid lymphoma (PTL) is a rare malignant thyroid tumor; its pathogenesis is closely related to chronic lymphocytic thyroiditis. The different pathological subtypes and stages of PTL have distinct clinical characteristics and prognosis, but the specific reasons are not clear. Wnt5a is a representative protein of non-canonical Wnt signaling. It plays an important role in many different types of tumors. This study is to explore the changes of Wnt5a and its receptor Ror2 in PTL development process and the clinical significance of their represent. We collected 22 PTL patient tumor specimens and clinical data. We observed the expression of Wnt5a and Ror2 in PTL tumor tissues by immunohistochemistry. Wnt5a was expressed positively in 12 (54.5 %) cases, and Ror2 was expressed positively in 18 (81.8 %) cases. The expression of Wnt5a had a significant difference in different pathological subtypes of PTL (P < 0.05). Wnt5a and Ror2 expression were associated with local invasion and clinical stage, respectively (P < 0.05), and had no significant correlation with age, gender, and tumor size. Although, no significant difference in overall survival was found between positive and negative groups of Wnt5a (P = 0.416) or Ror2 (P = 0.256), respectively. We still consider that Wnt5a and Ror2 play a complex and subtle role in the pathogenesis and progression of PTL and may become potential biomarkers and therapeutic targets of PTL.
Literature
1.
Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol. 1999;26:316–23.PubMed
2.
Pedersen RK, Pedersen NT. Primary non-Hodgkin’s lymphoma of the thyroid gland: a population based study. Histopathology. 1996;28(1):25–32.CrossRefPubMed
3.
Hwang YC, Kim TY, Kim WB, et al. Clinical characteristics of primary thyroid lymphoma in Koreans. Endocr J. 2009;56(3):399–405.CrossRefPubMed
4.
Graff-Baker A, Roman SA, Thomas DC. Prognosis of primary thyroid lymphoma: demographic, clinical and pathologic predictors of survival in 1408 cases. Surgery. 2009;146(6):1105–15.CrossRefPubMed
5.
6.
Kossev P, Livolsi V. Lymphoid lesions of the thyroid: review in light of the revised European American lymphoma classification and upcoming World Health Organization classification. Thyroid. 1999;9:1273–80.CrossRefPubMed
7.
Katna R, Shet T, Sengar M. Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center. Head Neck. 2013;35(2):165–71.CrossRefPubMed
8.
Sakorafas GH, Kokkoris P, Farley DR. Primary thyroid lymphoma (correction of lympoma): diagnostic and therapeutic dilemmas. Surg Oncol. 2010;19(4):e124–9.CrossRefPubMed
9.
Cha H, Kim JW, Suh CO. Patterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study. Radiat Oncol J. 2013;31(4):177–84.CrossRefPubMedPubMedCentral
10.
Ruggiero FP, Frauenhoffer E, Stack BC. Thyroid lymphoma: a single institution’s experience. Otolaryngol Head Neck Surg. 2005;133:888–96.CrossRefPubMed
11.
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.CrossRefPubMed
12.
Verkaar F, Zaman GJ. A model for signaling specificity of Wnt/Frizzled combinations through co-receptor recruitment. FEBS Lett. 2010;584(18):3850–4.CrossRefPubMed
13.
Pukrop T, Klemm F, Hagemann T, et al. Wnt5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci U S A. 2006;103:5454–9.CrossRefPubMedPubMedCentral
14.
O’Connell MP, Fiori JL, Xu M, et al. The orphan tyrosine kinase receptor, Ror2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29:34–44.CrossRefPubMed
15.
Ripka S, Konig A, Buchholz M, et al. WNT5A—target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis. 2007;28:1178–87.CrossRefPubMed
16.
Yamamoto H, Kitadai Y, Yamamoto H, et al. Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells. Gastroenterology. 2009;137(1):242–52. 252.e1-6.CrossRefPubMed
17.
Enomoto M, Hayakawa S, Itsukushima S, et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene. 2009;28(36):3197–208.CrossRefPubMed
18.
He F, Xiong W, Yu X, et al. Wnt5a regulates directional cell migration and cell proliferation via Ror2-mediated noncanonical pathway in mammalian palate development. Development. 2008;135:3871–9.CrossRefPubMedPubMedCentral
19.
20.
Kremenevskaja N, von Wasielewski R, Rao AS, et al. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene. 2005;24(13):2144–54.CrossRefPubMed
21.
Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973–2003. Cancer Causes Control. 2008;19:841–58.CrossRefPubMed
22.
Thieblemont C, Mayer A, Dumontet C, et al. Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab. 2002;87(1):105–11.CrossRefPubMed
23.
Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010;20(1):65–71.CrossRefPubMed
24.
25.
Kim J, Kim DW, Chang W, et al. Wnt5a is secreted by follicular dendritic cells to protect germinal center B cells via Wnt/Ca2+/NFAT/NF-κB-B cell lymphoma 6 signaling. J Immunol. 2012;188(1):182–9.CrossRefPubMed
26.
Lee JM, Kim IS, Kim H, et al. RORalpha attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation in colon cancer. Mol Cell. 2010;37(2):183–95.CrossRefPubMed
27.
Topol L, Jiang X, Choi H, et al. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J Cell Biol. 2003;162(5):899–908.CrossRefPubMedPubMedCentral
28.
Sato A, Yamamoto H, Sakane H, et al. Wnt5a regulates distinct signalling pathways by binding to Frizzled2. EMBO J. 2010;29(1):41–54.CrossRefPubMed
29.
Blanc E, Roux GL, Bénard J, et al. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene. 2005;24(7):1277–83.CrossRefPubMed
30.
Leris AC, Roberts TR, Jiang WG, et al. WNT5A expression in human breast cancer. Anticancer Res. 2005;25(2A):731–4.PubMed
31.
Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002;1(3):279–88.CrossRefPubMed
32.
Da Forno PD, Pringle JH, Hutchinson P, et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res. 2008;14(18):5825–32.CrossRefPubMed
33.
Liang H, Chen Q, Coles AH, et al. Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell. 2003;4(5):349–60.CrossRefPubMed
34.
Nishita M, Yoo SK, Nomachi A, et al. Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration. J Cell Biol. 2006;175(4):555–62.CrossRefPubMedPubMedCentral
35.
Yamamoto S, Nishimura O, Misaki K, et al. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell. 2008;15(1):23–36.CrossRefPubMed
36.
Grumolato L, Liu G, Mong P, et al. Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev. 2010;24(22):2517–30.CrossRefPubMedPubMedCentral
37.
Wright TM, Brannon AR, Gordan JD, et al. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene. 2009;28(27):2513–23.CrossRefPubMedPubMedCentral
38.
Metadata
Title
Wnt5a and Ror2 expression associate with the disease progress of primary thyroid lymphoma
Authors
Lei Wang
Dong Yang
Ying-Hou Wang
Xi Li
Hong-Ming Gao
Jun-Yuan Lv
Lei Wang
Shi-Jie Xin
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4471-2

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Original Article

SLC27A4 regulate ATG4B activity and control reactions to chemotherapeutics-induced autophagy in human lung cancer cells

Original Article

Association between interleukin 8 −251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population: a case–control study

Original Article

Prognostic significance of GPC5 expression in patients with prostate cancer

Original Article

Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway

Original Article

MiR-195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1

Original Article

Lysophosphatidic acid activates the RhoA and NF-κB through Akt/IκBα signaling and promotes prostate cancer invasion and progression by enhancing functional invadopodia formation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits